Published in Int J Radiat Oncol Biol Phys on November 17, 2010
Combining radiotherapy and cancer immunotherapy: a paradigm shift. J Natl Cancer Inst (2013) 3.07
Radiation as an immunological adjuvant: current evidence on dose and fractionation. Front Oncol (2012) 1.76
CDKN1A regulates Langerhans cell survival and promotes Treg cell generation upon exposure to ionizing irradiation. Nat Immunol (2015) 1.73
Maximizing tumor immunity with fractionated radiation. Int J Radiat Oncol Biol Phys (2011) 1.60
The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence. Nat Rev Cancer (2015) 1.43
Trial Watch: Anticancer radioimmunotherapy. Oncoimmunology (2013) 1.31
Cytokines in radiobiological responses: a review. Radiat Res (2012) 1.29
Strategies for optimizing the response of cancer and normal tissues to radiation. Nat Rev Drug Discov (2013) 1.25
The abscopal effect of local radiotherapy: using immunotherapy to make a rare event clinically relevant. Cancer Treat Rev (2015) 1.22
Role of T lymphocytes in tumor response to radiotherapy. Front Oncol (2012) 1.12
Human prostate tumor antigen-specific CD8+ regulatory T cells are inhibited by CTLA-4 or IL-35 blockade. J Immunol (2012) 1.09
The confluence of radiotherapy and immunotherapy. Front Oncol (2012) 1.06
The confluence of stereotactic ablative radiotherapy and tumor immunology. Clin Dev Immunol (2011) 1.05
The effect of radiation on the immune response to cancers. Int J Mol Sci (2014) 1.03
Physical modalities inducing immunogenic tumor cell death for cancer immunotherapy. Oncoimmunology (2015) 1.02
Combinations of immunotherapy and radiation in cancer therapy. Front Oncol (2014) 1.01
Inflammation and immunity in radiation damage to the gut mucosa. Biomed Res Int (2013) 1.00
Effects of adjuvant chemoradiotherapy on the frequency and function of regulatory T cells in patients with head and neck cancer. Clin Cancer Res (2013) 0.98
Regulatory T cells in radiotherapeutic responses. Front Oncol (2012) 0.98
T lymphocytes and normal tissue responses to radiation. Front Oncol (2012) 0.86
Thorax irradiation triggers a local and systemic accumulation of immunosuppressive CD4+ FoxP3+ regulatory T cells. Radiat Oncol (2014) 0.85
Strategies for combining immunotherapy with radiation for anticancer therapy. Immunotherapy (2015) 0.84
Radiation-induced autophagy potentiates immunotherapy of cancer via up-regulation of mannose 6-phosphate receptor on tumor cells in mice. Cancer Immunol Immunother (2014) 0.83
mRNA-based vaccines synergize with radiation therapy to eradicate established tumors. Radiat Oncol (2014) 0.83
Effects of tumor irradiation on host T-regulatory cells and systemic immunity in the context of adoptive T-cell therapy in mice. J Immunother (2013) 0.80
Ionizing radiation selectively reduces skin regulatory T cells and alters immune function. PLoS One (2014) 0.80
Combining Radiation Therapy with Immune Checkpoint Blockade for Central Nervous System Malignancies. Front Oncol (2016) 0.78
Effects of radiation on T regulatory cells in normal states and cancer: mechanisms and clinical implications. Am J Cancer Res (2015) 0.78
Developmental regulation of p53-dependent radiation-induced thymocyte apoptosis in mice. Clin Exp Immunol (2015) 0.77
Partial depletion of regulatory T cells does not influence the inflammation caused by high dose hemi-body irradiation. PLoS One (2013) 0.77
A hypofractionated radiation regimen avoids the lymphopenia associated with neoadjuvant chemoradiation therapy of borderline resectable and locally advanced pancreatic adenocarcinoma. J Immunother Cancer (2016) 0.76
Older age impacts radiotherapy-related outcomes in soft tissue sarcoma. J Surg Res (2015) 0.75
The intersection of radiotherapy and immunotherapy: mechanisms and clinical implications. Sci Immunol (2016) 0.75
DR3 signaling modulates the function of Foxp3+ regulatory T cells and the severity of acute graft versus host disease. Blood (2016) 0.75
Reply to: "Subverting misconceptions about radiation therapy". Nat Immunol (2016) 0.75
INFα-2b inhibitory effects on CD4(+)CD25(+)FOXP3(+) regulatory T cells in the tumor microenvironment of C57BL/6 J mice with melanoma xenografts. BMC Cancer (2016) 0.75
The Abscopal Effect of Radiation Therapy: What Is It and How Can We Use It in Breast Cancer? Curr Breast Cancer Rep (2017) 0.75
Immunotherapy for neuro-oncology: the critical rationale for combinatorial therapy. Neuro Oncol (2015) 0.75
Radiotherapy and immunotherapy: a beneficial liaison? Nat Rev Clin Oncol (2017) 0.75
Radiotherapy and MVA-MUC1-IL-2 vaccine act synergistically for inducing specific immunity to MUC-1 tumor antigen. J Immunother Cancer (2017) 0.75
Radiotherapy and immune checkpoint blockades: a snapshot in 2016. Radiat Oncol J (2016) 0.75
A Century of Radiation Therapy and Adaptive Immunity. Front Immunol (2017) 0.75
Blocking HIF-1α following radiotherapy to prolong and enhance the immune effects of radiotherapy: a hypothesis. Med Sci Monit (2014) 0.75
The Role of Lymphocytes in Radiotherapy-Induced Adverse Late Effects in the Lung. Front Immunol (2016) 0.75
Combining Oncolytic Adenovirus with Radiation-A Paradigm for the Future of Radiosensitization. Front Oncol (2017) 0.75
Uncovering the immune tumor microenvironment in non-small cell lung cancer to understand response rates to checkpoint blockade and radiation. Transl Lung Cancer Res (2017) 0.75
Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med (2003) 26.05
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med (2004) 22.96
Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol (2004) 17.40
CD4+ CD25+ suppressor T cells: more questions than answers. Nat Rev Immunol (2002) 12.73
Natural versus adaptive regulatory T cells. Nat Rev Immunol (2003) 8.74
A well adapted regulatory contrivance: regulatory T cell development and the forkhead family transcription factor Foxp3. Nat Immunol (2005) 6.77
Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol (2002) 6.60
Cutting edge: cure of colitis by CD4+CD25+ regulatory T cells. J Immunol (2003) 5.94
Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest (2005) 5.30
Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin Cancer Res (2009) 4.58
Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-beta signals in vivo. Proc Natl Acad Sci U S A (2004) 4.12
IL-2, regulatory T cells, and tolerance. J Immunol (2004) 3.13
TGF-beta1 and radiation fibrosis: a master switch and a specific therapeutic target? Int J Radiat Oncol Biol Phys (2000) 2.97
Regulatory T cells dynamically control the primary immune response to foreign antigen. J Immunol (2007) 2.55
Generation and accumulation of immunosuppressive adenosine by human CD4+CD25highFOXP3+ regulatory T cells. J Biol Chem (2009) 2.18
CD4+CD25high T cells are enriched in the tumor and peripheral blood of prostate cancer patients. J Immunol (2006) 2.18
Hypoxia-adenosinergic immunosuppression: tumor protection by T regulatory cells and cancerous tissue hypoxia. Clin Cancer Res (2008) 1.84
Antigen-specific FoxP3-transduced T-cells can control established type 1 diabetes. Diabetes (2004) 1.73
Increased ectonucleotidase expression and activity in regulatory T cells of patients with head and neck cancer. Clin Cancer Res (2009) 1.66
T-cell responses to survivin in cancer patients undergoing radiation therapy. Clin Cancer Res (2008) 1.61
Ionizing radiation affects human MART-1 melanoma antigen processing and presentation by dendritic cells. J Immunol (2004) 1.44
Control of IFN-alphaA by CD73: implications for mucosal inflammation. J Immunol (2008) 1.34
Adenosine A2A receptor antagonists: blockade of adenosinergic effects and T regulatory cells. Br J Pharmacol (2008) 1.30
A2A adenosine receptor may allow expansion of T cells lacking effector functions in extracellular adenosine-rich microenvironments. J Immunol (2009) 1.27
The requirement of multimodal therapy (vaccine, local tumor radiation, and reduction of suppressor cells) to eliminate established tumors. Clin Cancer Res (2005) 1.20
Gamma-ray resistance of regulatory CD4+CD25+Foxp3+ T cells in mice. Radiat Res (2010) 1.12
Impact of localized radiotherapy on blood immune cells counts and function in humans. Radiother Oncol (1999) 1.10
Abdominal radiation exposure elicits inflammatory responses and abscopal effects in the lungs of mice. Radiat Res (2005) 1.05
Toxicity risk of non-target organs at risk receiving low-dose radiation: case report. Radiat Oncol (2009) 1.01
Heightened NTPDase-1/CD39 expression and angiogenesis in radiation proctitis. Purinergic Signal (2009) 0.82
Tetracycline-regulated intratumoral expression of interleukin-3 enhances the efficacy of radiation therapy for murine prostate cancer. Cancer Gene Ther (2006) 0.81
The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation. J Natl Cancer Inst (2006) 10.06
Young dentate granule cells mediate pattern separation, whereas old granule cells facilitate pattern completion. Cell (2012) 4.71
Effects of radiation on normal tissue: consequences and mechanisms. Lancet Oncol (2003) 3.70
Current developments in cancer vaccines and cellular immunotherapy. J Clin Oncol (2003) 2.87
Animal models for medical countermeasures to radiation exposure. Radiat Res (2010) 2.83
Evaluation of high ipsilateral subventricular zone radiation therapy dose in glioblastoma: a pooled analysis. Int J Radiat Oncol Biol Phys (2013) 2.61
Report of the AAPM Task Group No. 105: Issues associated with clinical implementation of Monte Carlo-based photon and electron external beam treatment planning. Med Phys (2007) 2.47
Use of metal oxide nanoparticle band gap to develop a predictive paradigm for oxidative stress and acute pulmonary inflammation. ACS Nano (2012) 2.35
Models for evaluating agents intended for the prophylaxis, mitigation and treatment of radiation injuries. Report of an NCI Workshop, December 3-4, 2003. Radiat Res (2004) 2.33
Combining radiotherapy and immunotherapy: a revived partnership. Int J Radiat Oncol Biol Phys (2005) 2.29
A sense of danger from radiation. Radiat Res (2004) 2.02
The feasibility of a scanner-independent technique to estimate organ dose from MDCT scans: using CTDIvol to account for differences between scanners. Med Phys (2010) 1.97
A method to generate equivalent energy spectra and filtration models based on measurement for multidetector CT Monte Carlo dosimetry simulations. Med Phys (2009) 1.94
Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma. Clin Cancer Res (2003) 1.83
Molecular response to cetuximab and efficacy of preoperative cetuximab-based chemoradiation in rectal cancer. J Clin Oncol (2009) 1.82
Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma. Clin Cancer Res (2009) 1.81
Radiation resistance of cancer stem cells: the 4 R's of radiobiology revisited. Stem Cells (2010) 1.78
The feasibility of patient size-corrected, scanner-independent organ dose estimates for abdominal CT exams. Med Phys (2011) 1.77
Multifunctional T-cell analyses to study response and progression in adoptive cell transfer immunotherapy. Cancer Discov (2013) 1.68
The biological effectiveness of antiproton irradiation. Radiother Oncol (2006) 1.66
Use of coated silver nanoparticles to understand the relationship of particle dissolution and bioavailability to cell and lung toxicological potential. Small (2013) 1.62
T-cell responses to survivin in cancer patients undergoing radiation therapy. Clin Cancer Res (2008) 1.61
Maximizing tumor immunity with fractionated radiation. Int J Radiat Oncol Biol Phys (2011) 1.60
Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanoma. J Transl Med (2008) 1.56
Radiation dose to the fetus for pregnant patients undergoing multidetector CT imaging: Monte Carlo simulations estimating fetal dose for a range of gestational age and patient size. Radiology (2008) 1.53
The combination of ionizing radiation and peripheral vaccination produces long-term survival of mice bearing established invasive GL261 gliomas. Clin Cancer Res (2006) 1.51
Intratumoral immune cell infiltrates, FoxP3, and indoleamine 2,3-dioxygenase in patients with melanoma undergoing CTLA4 blockade. Clin Cancer Res (2009) 1.49
A phase I/II trial testing immunization of hepatocellular carcinoma patients with dendritic cells pulsed with four alpha-fetoprotein peptides. Clin Cancer Res (2006) 1.48
Surface charge and cellular processing of covalently functionalized multiwall carbon nanotubes determine pulmonary toxicity. ACS Nano (2013) 1.47
Challenges in linear accelerator radiotherapy for chordomas and chondrosarcomas of the skull base: focus on complications. Int J Radiat Oncol Biol Phys (2011) 1.47
Capsaicin, a component of red peppers, inhibits the growth of androgen-independent, p53 mutant prostate cancer cells. Cancer Res (2006) 1.45
Ionizing radiation affects human MART-1 melanoma antigen processing and presentation by dendritic cells. J Immunol (2004) 1.44
Intraoperative ultrasonography-guided positioning of iodine 125 plaque brachytherapy in the treatment of choroidal melanoma. Ophthalmology (2012) 1.43
CTLA4 blockade induces frequent tumor infiltration by activated lymphocytes regardless of clinical responses in humans. Clin Cancer Res (2011) 1.42
National Institutes of Health funding in radiation oncology: a snapshot. Int J Radiat Oncol Biol Phys (2013) 1.42
Dose to radiosensitive organs during routine chest CT: effects of tube current modulation. AJR Am J Roentgenol (2009) 1.41
Pluronic F108 coating decreases the lung fibrosis potential of multiwall carbon nanotubes by reducing lysosomal injury. Nano Lett (2012) 1.40
Role of dendritic cell phenotype, determinant spreading, and negative costimulatory blockade in dendritic cell-based melanoma immunotherapy. J Immunother (2004) 1.40
Molecular mechanisms of late normal tissue injury. Semin Radiat Oncol (2007) 1.40
Enhanced antitumor activity induced by adoptive T-cell transfer and adjunctive use of the histone deacetylase inhibitor LAQ824. Cancer Res (2009) 1.38
Definition of an immunologic response using the major histocompatibility complex tetramer and enzyme-linked immunospot assays. Clin Cancer Res (2006) 1.37
Ionizing radiation activates the Nrf2 antioxidant response. Cancer Res (2010) 1.35
Immunomodulation by imiquimod in patients with high-risk primary melanoma. J Invest Dermatol (2011) 1.34
The human immunodeficiency virus (HIV)-1 protease inhibitor saquinavir inhibits proteasome function and causes apoptosis and radiosensitization in non-HIV-associated human cancer cells. Cancer Res (2002) 1.31
Effects of recombinant erythropoietin on breast cancer-initiating cells. Neoplasia (2007) 1.29
Cytokines in radiobiological responses: a review. Radiat Res (2012) 1.29
Macrophages from irradiated tumors express higher levels of iNOS, arginase-I and COX-2, and promote tumor growth. Int J Radiat Oncol Biol Phys (2007) 1.28
After the bomb drops: a new look at radiation-induced multiple organ dysfunction syndrome (MODS). Int J Radiat Biol (2011) 1.24
T-cell responses to HLA-A*0201 immunodominant peptides derived from alpha-fetoprotein in patients with hepatocellular cancer. Clin Cancer Res (2003) 1.24
Determinant spreading and tumor responses after peptide-based cancer immunotherapy. Trends Immunol (2003) 1.23
Links between innate immunity and normal tissue radiobiology. Radiat Res (2010) 1.19
Irradiation of the potential cancer stem cell niches in the adult brain improves progression-free survival of patients with malignant glioma. BMC Cancer (2010) 1.19
Radiotherapy decreases vascular density and causes hypoxia with macrophage aggregation in TRAMP-C1 prostate tumors. Clin Cancer Res (2009) 1.19
Adenovirus MART-1-engineered autologous dendritic cell vaccine for metastatic melanoma. J Immunother (2008) 1.18
Hypoxia in human colorectal adenocarcinoma: comparison between extrinsic and potential intrinsic hypoxia markers. Int J Radiat Oncol Biol Phys (2006) 1.12
Surface interactions with compartmentalized cellular phosphates explain rare earth oxide nanoparticle hazard and provide opportunities for safer design. ACS Nano (2014) 1.12
Compartmental responses after thoracic irradiation of mice: strain differences. Int J Radiat Oncol Biol Phys (2005) 1.11
NK and CD4 cells collaborate to protect against melanoma tumor formation in the brain. J Immunol (2006) 1.08
Radiation responses of cancer stem cells. J Cell Biochem (2009) 1.08
Anthracyclines, proteasome activity and multi-drug-resistance. BMC Cancer (2005) 1.08
The confluence of stereotactic ablative radiotherapy and tumor immunology. Clin Dev Immunol (2011) 1.05
Attenuation of iodine 125 radiation with vitreous substitutes in the treatment of uveal melanoma. Arch Ophthalmol (2010) 1.04
Refinement of the dichlorofluorescein assay for flow cytometric measurement of reactive oxygen species in irradiated and bystander cell populations. Radiat Res (2008) 1.04
The feasibility of a regional CTDIvol to estimate organ dose from tube current modulated CT exams. Med Phys (2013) 1.04
Human dendritic cell maturation by adenovirus transduction enhances tumor antigen-specific T-cell responses. J Immunother (2004) 1.03
The role of the ubiquitin/proteasome system in cellular responses to radiation. Oncogene (2003) 1.03
Prostratin and bortezomib are novel inducers of latent Kaposi's sarcoma-associated herpesvirus. Antivir Ther (2005) 1.02
NADPH Oxidase-Dependent NLRP3 Inflammasome Activation and its Important Role in Lung Fibrosis by Multiwalled Carbon Nanotubes. Small (2015) 1.02
High-throughput screening identifies two classes of antibiotics as radioprotectors: tetracyclines and fluoroquinolones. Clin Cancer Res (2009) 1.02
Adoptive transfer of MART-1 T-cell receptor transgenic lymphocytes and dendritic cell vaccination in patients with metastatic melanoma. Clin Cancer Res (2014) 1.01
N-acetyl-L-cysteine inhibits 26S proteasome function: implications for effects on NF-kappaB activation. Free Radic Biol Med (2002) 1.01
Bronchoalveolar lavage and interstitial cells have different roles in radiation-induced lung injury. Int J Radiat Biol (2003) 1.00
Allelic exclusion and peripheral reconstitution by TCR transgenic T cells arising from transduced human hematopoietic stem/progenitor cells. Mol Ther (2013) 1.00
Engineering an effective immune adjuvant by designed control of shape and crystallinity of aluminum oxyhydroxide nanoparticles. ACS Nano (2013) 0.99
SOCS3 regulates p21 expression and cell cycle arrest in response to DNA damage. Cell Signal (2008) 0.98
Spontaneous and vaccine induced AFP-specific T cell phenotypes in subjects with AFP-positive hepatocellular cancer. Cancer Immunol Immunother (2007) 0.98
Regulatory T cells in radiotherapeutic responses. Front Oncol (2012) 0.98
The proteasome inhibitor MG-132 sensitizes PC-3 prostate cancer cells to ionizing radiation by a DNA-PK-independent mechanism. BMC Cancer (2005) 0.97
Preparing for the future of radiation oncology. J Am Coll Radiol (2007) 0.97
Stereotactic radiation treatment for recurrent nonbenign meningiomas. J Neurosurg (2007) 0.97
Spinal cord tolerance to single-fraction partial-volume irradiation: a swine model. Int J Radiat Oncol Biol Phys (2010) 0.96
Hyperthermia-induced proteasome inhibition and loss of androgen receptor expression in human prostate cancer cells. Cancer Res (2005) 0.96
Functional phenotype of macrophages depends on assay procedures. Int Immunol (2007) 0.95
Retracted Molecular mechanism of MART-1+/A*0201+ human melanoma resistance to specific CTL-killing despite functional tumor-CTL interaction. Cancer Res (2010) 0.95
Aspect ratio plays a role in the hazard potential of CeO2 nanoparticles in mouse lung and zebrafish gastrointestinal tract. ACS Nano (2014) 0.95
Immunosensitization of tumor cells to dendritic cell-activated immune responses with the proteasome inhibitor bortezomib (PS-341, Velcade). J Immunol (2006) 0.95